PD-protec® s a solution for peritoneal dialysis (PD). The product is being developed to significantly improve and prolong the survival of patients undergoing PD.
A clinical Phase I/II trial with PD-protec® demonstrated the clinical safety of PD-protec® and provided promising data on beneficial effects in respect to peritoneal stress response (reduction of oxidative stress and inflammation in patients suffering from peritonitis).
Treatment with PD-protec® also yielded first evidence of improved peritoneal immunocompetence.
A randomized, blinded, multicenter Phase II trial is planned to commence at the end of Q2 2014.
The active substance in PD-protec® is alanyl-glutamine, a dipeptide with a pharmacological and tolerability profile that is well-proven in parenteral (intravenous) nutrition.
PD-protec® is patent protected.